2024 World Conference on Lung Cancer (WCLC) - Posters-P2.14B.05 eVOLVE-Meso: A Global Phase 3 Study of First-Line Volrustomig Plus Chemotherapy in Unresectable Pleural Mesothelioma

P2.14B.05 eVOLVE-Meso: A Global Phase 3 Study of First-Line Volrustomig Plus Chemotherapy in Unresectable Pleural Mesothelioma

Back to course

Pdf Summary

The eVOLVE-Meso study is a global Phase 3 clinical trial focused on evaluating the efficacy of a new immunotherapy agent called volrustomig in combination with chemotherapy for the treatment of unresectable pleural mesothelioma (PM), a highly aggressive cancer affecting the lung lining. Volrustomig is a bispecific monoclonal antibody designed to target and inhibit PD-1 and CTLA-4 proteins on T-cells, stimulating an enhanced immune response to cancer cells.<br /><br />This study involves about 600 participants newly diagnosed with PM who are unsuitable for surgical treatment due to the advanced state of their disease. Participants will be randomly assigned to either receive volrustomig with chemotherapy or standard care, which includes chemotherapy paired with either nivolumab and ipilimumab for patients with epithelioid PM, or just nivolumab and ipilimumab for those with non-epithelioid PM.<br /><br />Patients will be closely monitored for overall survival (OS), progression-free survival (PFS), objective response rate (ORR), adverse events, and the immunogenicity of volrustomig. The primary objective is to assess whether volrustomig combined with chemotherapy provides better survival outcomes than existing standard treatments.<br /><br />The trial, supported by AstraZeneca, began enrollment in November 2023 and aims to complete by March 2027. Enrollment is taking place in various countries, including the USA, UK, China, and Brazil. The study hopes to address the unmet medical needs of PM patients, as recent advancements in immunotherapy have shown promise but have not yet significantly changed the poor prognosis associated with this disease.<br /><br />More detailed information is available on ClinicalTrials.gov, and individuals interested in participating or learning more are encouraged to consult their healthcare providers.

Asset Subtitle

Arnaud Scherpereel

Meta Tag

Speaker Arnaud Scherpereel

Topic Mesothelioma, Thymoma & Other Thoracic Tumors

Keywords

eVOLVE-Meso

volrustomig

immunotherapy

pleural mesothelioma

clinical trial

PD-1

CTLA-4

AstraZeneca

chemotherapy

survival outcomes